Widely prescribed blood pressure drugs linked to 33% higher kidney risk in type 2 diabetes
A study presented at the ERA Congress links dihydropyridine calcium-channel blockers (DCCBs) to a 33% higher risk of kidney failure in type 2 diabetes patients. This finding is significant even for patients already using standard kidney-protective medications like RAS and SGLT2 inhibitors.
Why it matters
The findings could lead to changes in clinical guidelines for managing blood pressure in diabetic patients to prevent kidney damage.
New findings presented at the 63rd ERA Congress suggest that a commonly prescribed group of blood pressure drugs may be linked to worse kidney outcomes in people with type 2 diabetes (T2D), including patients already taking newer medications designed to protect kidney function.
The medications, known as dihydropyridine calcium-channel blockers (DCCBs), lower blood pressure by relaxing blood vessels. They are often prescribed as second-line treatments for people with diabetic kidney disease (DKD). In the new study, patients who took DCCBs in addition to standard therapies experienced a significantly greater risk of major adverse kidney events than patients treated with other blood pressure medications.
Protecting the Kidneys in Type 2 Diabetes
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in